Corvus Pharma's Soquelitinib Shows Durable Remissions, Favorable Safety in Phase 1 Trial
CRVS has more than doubled off its 52-week low of $3.38.
Summary
Corvus Pharmaceuticals announced positive Phase 1 clinical trial data for its drug candidate, soquelitinib, demonstrating durable, drug-free remissions and a favorable safety profile. The data, presented today and based on an 8-K filing, showed dose-dependent efficacy and additional benefits with longer treatment, with a safety profile comparable to placebo. This early-stage validation of soquelitinib's potential is a significant positive for the company, bolstering confidence in its pipeline. Investors will now closely monitor the drug's progression into later-stage clinical trials and any subsequent regulatory developments.
At the time of this announcement, CRVS was trading at $16.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $3.38 to $26.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.